These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 8823230)

  • 1. Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects.
    Weber C; Schmitt R; Birnboeck H; Hopfgartner G; van Marle SP; Peeters PA; Jonkman JH; Jones CR
    Clin Pharmacol Ther; 1996 Aug; 60(2):124-37. PubMed ID: 8823230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacodynamics of the ETA-selective endothelin receptor antagonist SPP301 in healthy human subjects.
    Dieterle W; Mann J; Kutz K
    J Clin Pharmacol; 2004 Jan; 44(1):59-66. PubMed ID: 14681342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators.
    Krum H; Viskoper RJ; Lacourciere Y; Budde M; Charlon V
    N Engl J Med; 1998 Mar; 338(12):784-90. PubMed ID: 9504938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absorption, excretion, and metabolism of the endothelin receptor antagonist bosentan in healthy male subjects.
    Weber C; Gasser R; Hopfgartner G
    Drug Metab Dispos; 1999 Jul; 27(7):810-5. PubMed ID: 10383925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective effects of non-peptide endothelin receptor antagonist bosentan on myocardial ischaemic and reperfusion injury in the pig.
    Wang QD; Li XS; Lundberg JM; Pernow J
    Cardiovasc Res; 1995 Jun; 29(6):805-12. PubMed ID: 7656284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Greater functional ETB receptor antagonism with bosentan than sitaxsentan in healthy men.
    MacIntyre IM; Dhaun N; Lilitkarntakul P; Melville V; Goddard J; Webb DJ
    Hypertension; 2010 Jun; 55(6):1406-11. PubMed ID: 20404221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple-dose pharmacokinetics, safety, and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteers.
    Weber C; Schmitt R; Birnboeck H; Hopfgartner G; Eggers H; Meyer J; van Marle S; Viischer HW; Jonkman JH
    J Clin Pharmacol; 1999 Jul; 39(7):703-14. PubMed ID: 10392325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative bioavailability of a newly developed pediatric formulation of bosentan vs. the adult formulation.
    Gutierrez MM; Nicolas LB; Donazzolo Y; Dingemanse J
    Int J Clin Pharmacol Ther; 2013 Jun; 51(6):529-36. PubMed ID: 23611572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of endothelin in the circulatory changes associated with small bowel strangulation obstruction in pigs: effects of the endothelin receptor antagonist bosentan.
    Fevang J; Ovrebø K; Myking O; Grong K; Svanes K
    J Surg Res; 2001 Apr; 96(2):224-32. PubMed ID: 11266277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacodynamics of SB 209670, an endothelin receptor antagonist: effects on the regulation of renal vascular tone.
    Freed MI; Wilson DE; Thompson KA; Harris RZ; Ilson BE; Jorkasky DK
    Clin Pharmacol Ther; 1999 May; 65(5):473-82. PubMed ID: 10340912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of effects of bosentan (Ro 47-0203), a nonpeptide endothelin ETA/ETB receptor antagonist, in the hind-limb vascular bed of the cat.
    Champion HC; Estrada LS; Estrada LN; Filep JG; Kadowitz PJ
    Can J Physiol Pharmacol; 1998 Feb; 76(2):141-7. PubMed ID: 9635152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Target-Mediated Drug Disposition Pharmacokinetic-Pharmacodynamic Model of Bosentan and Endothelin-1.
    Volz AK; Krause A; Haefeli WE; Dingemanse J; Lehr T
    Clin Pharmacokinet; 2017 Dec; 56(12):1499-1511. PubMed ID: 28401480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjects.
    Sidharta PN; van Giersbergen PL; Dingemanse J
    J Clin Pharmacol; 2013 Nov; 53(11):1131-8. PubMed ID: 23900878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist.
    Clozel M; Breu V; Gray GA; Kalina B; Löffler BM; Burri K; Cassal JM; Hirth G; Müller M; Neidhart W
    J Pharmacol Exp Ther; 1994 Jul; 270(1):228-35. PubMed ID: 8035319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers.
    Russell T; Stoltz M; Weir S
    Clin Pharmacol Ther; 1998 Dec; 64(6):612-21. PubMed ID: 9871426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonpeptide endothelin receptor antagonists. VI: Pharmacological characterization of SB 217242, a potent and highly bioavailable endothelin receptor antagonist.
    Ohlstein EH; Nambi P; Lago A; Hay DW; Beck G; Fong KL; Eddy EP; Smith P; Ellens H; Elliott JD
    J Pharmacol Exp Ther; 1996 Feb; 276(2):609-15. PubMed ID: 8632328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Receptor- and non-receptor-mediated clearance of big-endothelin and endothelin-1: differential effects of acute and chronic ETA receptor blockade.
    Burkhardt M; Barton M; Shaw SG
    J Hypertens; 2000 Mar; 18(3):273-9. PubMed ID: 10726713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of plasma endothelin-1 level after bosentan administration in pulmonary arterial hypertension.
    Hiramoto Y; Shioyama W; Higuchi K; Arita Y; Kuroda T; Sakata Y; Nakaoka Y; Fujio Y; Yamauchi-Takihara K
    J Cardiol; 2009 Jun; 53(3):374-80. PubMed ID: 19477379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo and in vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburide.
    van Giersbergen PL; Treiber A; Clozel M; Bodin F; Dingemanse J
    Clin Pharmacol Ther; 2002 Apr; 71(4):253-62. PubMed ID: 11956508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.